Cart
sales@molnova.com
Nidanilimab
CAS No. 2171061-85-9
Nidanilimab( —— )
Catalog No. M36753 CAS No. 2171061-85-9
Nidanilimab (CAN04) is a fully humanized IL1RAP monoclonal antibody with a Kd value of 1.10 pM. It exhibits antitumor activity by disrupting the IL1α and IL1β signaling pathways and inducing the immune system to destroy tumor cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 715 | In Stock |
|
| 10MG | 1121 | In Stock |
|
| 25MG | 1663 | In Stock |
|
| 50MG | 2186 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNidanilimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionNidanilimab (CAN04) is a fully humanized IL1RAP monoclonal antibody with a Kd value of 1.10 pM. It exhibits antitumor activity by disrupting the IL1α and IL1β signaling pathways and inducing the immune system to destroy tumor cells.
-
DescriptionNidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .
-
In Vitro——
-
In VivoAnimal Model:Nude C57Bl/6 mice with LU2503 NSCLC PDX model Dosage:10 mg/kg Administration:Intraperitoneal injection Result:Displayed a significantly stronger anti-tumor effect compared to isotype control with chemotherapy.
-
Synonyms——
-
PathwayApoptosis
-
TargetIL Receptor
-
RecptorIL Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2171061-85-9
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Millrud CR, et, al. The anti-IL1RAP antibody CAN04 increases tumor sensitivity to platinum-based chemotherapy.
molnova catalog
related products
-
IL-2-IN-1
IL-2-IN-1 is a potent inhibitor of IL-2 (IC50: 1978 nM) and demonstrates anti-proliferative effects.
-
CP 424174
CP 424174 is an inhibitor of IL-1β post-translational processing with IC50 of 210 nM. Inhibits the formation of mature IL-1β. Indirectly inhibits NLRP3. Active in vivo and orally bioavailable.
-
Benralizumab
Benralizumab (MEDI-563) is a monoclonal antibody targeting the interleukin-5 receptor alpha (IL-5Rα).
